Bristol-Myers Squibb, Karuna plan to refile US antitrust paperwork for deal focused on neuroscience drug
Bristol-Myers Squibb and Karuna Therapeutics pulled US antitrust paperwork for their deal and plan to refile on Feb. 12. The $14 billion transaction would boost Bristol-Myers Squibb’s neuroscience portfolio with Karuna’s...To view the full article, register now.
Already a subscriber? Click here to view full article